Covishield and Covaxin -- the two coronavirus vaccines currently in use in India -- have efficacy against the 'Indian strain' and show 'milder' illness in case of infection post vaccination, a senior scientist said on April 27 citing preliminary results of a study.
Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology (IGIB), said the study on effectiveness of the available vaccines on the B.1.617 variant of SARS-CoV2 suggests that post vaccination, the infections are milder.
The B.1.617 variant is also being called a 'double mutant' or the 'Indian strain'.
'Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections. This is a positive while we get quantitative data for better understanding of infection protection,' Agrawal tweeted.